BCAX vs MRK · $1.51B cap vs P/E 33, rev $16.61B
Bicara Therapeutics Inc. Common Stock (BCAX) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
BCAX does not have a complete income-statement cache yet.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
BCAX currently screens at market cap $1.51B. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the BCAX and MRK stock pages for the full models.
Not investment advice.